美国AMAG Pharma  
美国AMAG制药公司是一家生物制药公司，它在开发和推广缺铁性贫血上拥有专有的纳米技术，并且在诊断癌症和心血管疾病上拥有新型显像剂技术。Ferumoxytol 是该公司的主要产品，它是一种静脉补铁制剂，用于治疗慢性肾病患者的缺铁性贫血。

Core Technology of AMAG Pharmaceuticals, Inc.

Our core technology is based on the characteristic properties of ultra small, semi synthetic coated iron oxide particles. Our core competencies include the ability to design such particles for particular applications, to manufacture the particles in controlled sizes and to cover the particles with different coatings depending upon the application for which they will be used.

Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.

Iron - A Critical Element in the Body

Iron is critical to a number of processes in the human body and is a key component of the hemoglobin molecule where it serves a vital role in oxygen transport from the lungs to tissues. Low levels of iron in the body is known as iron deficiency and can result in anemia and inadequate oxygen delivery to different organs. Iron deficiency anemia can result when there is an inadequate amount of hemoglobin in red blood cells. Iron deficiency anemia is associated with a number of symptoms including fatigue, lethargy, poor concentration, shortness of breath, palpitations, and dizziness. Low levels of red blood cells can occur because of iron deficiency anemia, blood loss, and/or decreased production of the hormone erythropoietin. Intravenous iron replacement therapy plays a major role, along with erythropoietic stimulating agents, in treating certain types of chronic anemia in patients suffering from chronic kidney disease. Iron deficiency anemia is also common in patients with other conditions and diseases such as abnormal uterine bleeding, cancer and gastrointestinal diseases.